PIERIANDX

Company Overview

PierianDx is developing and marketing a clinical software platform for personalized medicine applications.

The company’s lead product, Clinical Genomics Workspace (CGW), gives clinicians the ability to store, process and report results from NGS-based cancer tests. The company offers this platform as a service for analyzing somatic cancer mutations and for constitution disorders including cardiomyopathy.

In December 2020, Pierian expanded an existing partnership with Illumina covering NGS-based cancer panel reporting. Under this partnership, PierianDx’s genomic reporting products, including the Clinical Genomics Workspace and Clinical Genomics Knowledgebase, will be enabled for use with the AmpliSeq for Illumina Focus panel, AmpliSeq for Illumina Myeloid panel and the Illumina TruSight Hereditary Cancer Panel.

In October 2020, PierianDx formed an alliance with Pillar Biosciences covering precision cancer care. PierianDx began integrating the Pilar Biosciences PiVAT cancer bioinformatics pipeline into its core technology platform. Pillar Bio also agreed to market PierianDx’s clinical genomic reports together with its own cancer profiling assays.

In September 2022, Pierian and Genome Medical announced a collaboration aimed at optimizing genomic testing programs. Through this collaboration, Genome Medical and Pierian are working together to streamline the identification of patients who may benefit from genomic testing, employing an enhanced clinical genomics workflow.

Company's Business Segments

• Biotechnology Research : This segment includes Clinical Genomics Workspace, Genomics Knowledgebase, Professional Services, IVD Partnerships.